Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 1, 2025Clinical and Translational ScienceOpen Access

Gender‐Affirming Hormone Therapy: Pharmacokinetic Considerations for Oncology in Transgender Patients

View Full Paper
Ask AI
Bookmark
Share

Authors

ACAnna CarolloLPLavinia PiazzaAPAlessio Provenzani

Discussion

Loading...

Member takes

Overview

Narrative review reveals the impacts of gender-affirming hormone therapy on renal function and drug dosing in oncology, suggesting personalized care is essential.

Key Points

  • The review addresses the pharmacokinetic challenges posed by gender-affirming hormone therapy in transgender patients receiving oncology treatment.
  • Examined clinical implications of gender-affirming hormone therapy in oncology
  • Focused on renal function parameters and biomarker assessments
  • Reviewed literature on dosing strategies and pharmacokinetics relative to transgender populations.
  • Gender-affirming hormone therapy affects renal function and pharmacokinetics in transgender patients
  • Alterations in body composition and muscle mass influence standard renal function calculations
  • Cystatin C is identified as a promising biomarker for renal function assessment in this population.

Cite This Study

Carollo et al. (2025) studied this question.

synapsesocial.com/papers/69254366c0ce034ddc358456https://doi.org/10.1111/cts.70396
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Nutritional Monitoring During Gender-Affirming Hormone Therapy: Body Composition and Metabolic Implications2026
  2. 2Safe and supportive prescribing in transgender and non‐binary patients with cancer2024
  3. 3Pharmaceutical Considerations for Oncology Risk, Screening, and Drug Dosing in the Transgender Population2026 · 1 citations
  4. 4Gender-affirming hormone therapy and cardiovascular health in transgender adults2024 · 3 citations
  5. 5Assessing and Addressing the Risk of Venous Thromboembolism Across the Spectrum of Gender Affirming Care: A Review2022 · 41 citations